Journal article
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
SpringerPlus, v 3(1), 471
27 Aug 2014
PMID: 25197623
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Recombinant factor VIIa (rFVIIa) can be used for rapid INR normalization in life-threatening hemorrhage in anticoagulated patients. Dosing is unclear and may carry thromboembolic risks. We reviewed the use of rFVIIa at a comprehensive stroke and cerebrovascular center to evaluate dose effectiveness on INR reduction and thromboembolic complications experienced. The primary endpoint was to review the efficacy of rFVIIa in lowering INR. Secondary endpoints included doses used and adverse effects caused by rFVIIa administration. Forty-one percent of patients presented with a subdural hemorrhage. The mean INR prior to rFVIIa administration was 3.5 (0.9-15) and decreased to 1.13 (0.6-2). The mean dose of rFVIIa given was 73 mcg/kg (±24 mcg/kg). Two patients (3%) experienced a thromboembolic event. Recombinant factor VIIa appears to lower INR without significant thromboembolic complications.
Metrics
Details
- Title
- Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
- Creators
- Natalie Yampolsky - Capital District Health AuthorityDouglas Stofko - Capital UniversityErol Veznedaroglu - Capital UniversityKenneth Liebman - Capital UniversityMandy J Binning - Capital University
- Publication Details
- SpringerPlus, v 3(1), 471
- Publisher
- Springer International Publishing
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology; Neurosurgery
- Web of Science ID
- WOS:000359080600001
- Scopus ID
- 2-s2.0-84920111315
- Other Identifier
- 991021917816504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Clinical Neurology